All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-02-01T12:51:09.000Z

What new technologies are available in the field of CAR T manufacturing?

By Alia Mohamed
Featured
Bruce Levine
Feb 1, 2020
Share:

Bookmark this article

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Bruce Levine from the University of Pennsylvania, Philadelphia, US, discusses what new technologies are available in the field of CAR T manufacturing.

Bruce Levine talks about novel technologies in CAR T cell manufacturing that will increase the effectiveness of CAR T such as the incorporation of biomarkers as a prognostic factor for response. In addition to this, he explains strategies such as shorting the process of CAR T manufacturing to reduce overall costs.

What new technologies are available in the field of CAR T manufacturing?

More about...
CAR therapyCAR-T 2020

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

How will CAR T therapy for lymphoma be used in the future?

Gilles Salles explains that the use of CAR T cells will expand in the future, as the current market approval is for patients in the third line of therapy with primary mediastinal B‐cell...

Feb 1, 2020
Add bookmark

How will CAR T therapy for lymphoma be used in the future?

Gilles Salles explains that the use of CAR T cells will expand in the future, as the current market approval is for patients in the third...

Feb 1, 2020
Add bookmark

How can third generation anti-CD30 CARs improve treatment of CD30+ lymphomas?

Biagio De Angelis, Ospedale Pediatrico Bambino Gesù, Rome, IT, discusses how third generation anti-CD30 CARs can improve treatment of CD30+ lymphomas.

Jan 30, 2020
Add bookmark

How can third generation anti-CD30 CARs improve treatment of CD30+ lymphomas?

Biagio De Angelis, Ospedale Pediatrico Bambino Gesù, Rome, IT, discusses how third generation anti-CD30 CARs can improve...

Jan 30, 2020

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox